Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 33, Issue 6, 2014, Pages 1029-1035

  Dong, H Y ^a   Xie, J ^a   Chen, L H ^a   Wang, T T ^a   Zhao, Y R ^a   Dong, Y L ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; LINEZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ABDOMINAL INFECTION; ADOLESCENT; ADULT; AGED; APACHE; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BACTERIAL CLEARANCE; BODY WEIGHT; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL PRACTICE; COAGULASE NEGATIVE STAPHYLOCOCCUS INFECTION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG SAFETY; ENTEROCOCCAL INFECTION; FEASIBILITY STUDY; FEMALE; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS INFECTION; VERY ELDERLY; YOUDEN INDEX; CHEMICALLY INDUCED; CRITICAL ILLNESS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; YOUNG ADULT;

ACETAMIDES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; DRUG MONITORING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 84903819274     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-013-2041-3     Document Type: Article

References (23)

1. Ament PW, Jamshed N, Horne JP (2002) Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections. Am Fam Physician 65(4):663-670 (Pubitemid 34175040)
2. Attassi K, Hershberger E, Alam R, Zervos MJ (2002) Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 34(5):695-698. doi:10.1086/338403 (Pubitemid 34165334)
3. Matsumoto K, Takeda Y, Takeshita A, Fukunaga N, Shigemi A, Yaji K, Shimodozono Y, Yamada K, Ikawa K, Morikawa N (2009) Renal function as a predictor of linezolid-induced thrombocytopenia. Int J Antimicrob Agents 33(1):98-99. doi:10.1016/j.ijantimicag.2008.07.002
4. Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ (2002) Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 46(8):2723-2726 (Pubitemid 34793498)
5. Antal EJ, Hendershot PE, Batts DH, Sheu WP, Hopkins NK, Donaldson KM (2001) Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol 41(5):552-562 (Pubitemid 32381873)
6. Renslo AR (2010) Antibacterial oxazolidinones: emerging structure-toxicity relationships. Expert Rev Anti Infect Ther 8(5):565-574. doi:10.1586/eri.10.26
7. McKee EE, Ferguson M, Bentley AT, Marks TA (2006) Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 50(6):2042-2049. doi:10.1128/AAC.01411-05 (Pubitemid 43807524)
8. Thallinger C, Buerger C, Plock N, Kljucar S, Wuenscher S, Sauermann R, Kloft C, Joukhadar C (2008) Effect of severity of sepsis on tissue concentrations of linezolid. J Antimicrob Chemother 61(1):173-176. doi:10.1093/jac/dkm431
9. Dong H, Wang X, Dong Y, Lei J, Li H, You H, Wang M, Xing J, Sun J, Zhu H (2011) Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents 38(4):296-300. doi:10.1016/j.ijantimicag.2011.05.007
10. Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, Viale P (2010) Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 54(11):4605-4610. doi:10.1128/AAC.00177-10
11. Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Kobayashi T, Sadoh S, Morita K, Kamimura H, Karube Y (2011) Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother 17(1):70-75. doi:10.1007/s10156-010-0080-6
12. Matsumoto K, Takeshita A, Ikawa K, Shigemi A, Yaji K, Shimodozono Y, Morikawa N, Takeda Y, Yamada K (2010) Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents 36(2):179-181. doi:10.1016/j.ijantimicag.2010.02.019
13. Hiraki Y, Tsuji Y, Hiraike M, Misumi N, Matsumoto K, Morita K, Kamimura H, Karube Y (2012) Correlation between serum linezolid concentration and the development of thrombocytopenia. Scand J Infect Dis 44(1):60-64. doi:10.3109/00365548.2011.608712
14. Lin YH, Wu VC, Tsai IJ, Ho YL, Hwang JJ, Tsau YK, Wu CY, Wu KD, Hsueh PR (2006) High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents 28(4):345-351. doi:10.1016/j.ijantimicag.2006.04.017
15. Soriano A, Ortega M, Garcia S, Penarroja G, Bove A, Marcos M, Martinez JC, Martinez JA, Mensa J (2007) Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Antimicrob Agents Chemother 51(7):2559-2563. doi:10.1128/AAC.00247-07 (Pubitemid 47047337)
16. Grau S, Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Alvarez-Lerma F (2005) Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia. J Antimicrob Chemother 56(2):440-441. doi:10.1093/jac/dki202 (Pubitemid 41158548)
17. Hiraki Y, Tsuji Y, Matsumoto K, Morita K, Kamimura H, Karube Y (2011) Influence of linezolid clearance on the induction of thrombocytopenia and reduction of hemoglobin. Am J Med Sci 342(6):456-460. doi:10.1097/MAJ. 0b013e318218cf18
18. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31-41
19. Niwa T, Suzuki A, Sakakibara S, Kasahara S, Yasuda M, Fukao A, Matsuura K, Goto C, Murakami N, Itoh Y (2009) Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy. Clin Ther 31(10):2126-2133. doi:10.1016/j.clinthera.2009.10.017
20. Wu VC, Wang YT, Wang CY, Tsai IJ, Wu KD, Hwang JJ, Hsueh PR (2006) High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis 42(1):66-72. doi:10.1086/498509
21. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ (2003) Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 42(15):1411-1423 (Pubitemid 38054365)
22. Jones RN, Fritsche TR, Sader HS, Ross JE (2007) Zyvox annual appraisal of potency and spectrum program results for 2006: an activity and spectrumanalysis of linezolid using clinical isolates from 16 countries. Diagn Microbiol Infect Dis 59(2):199-209. doi:10.1016/j.diagmicrobio.2007.06.001 (Pubitemid 47484135)
23. Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M (2012) Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 67(8):2034-2042. doi:10.1093/jac/dks153